STK15/Aurora2 is a centrosome-associated serine/threonine kinase, the protein levels and kinase activity of which rise during G2 and mitosis. STK15 overexpression induces tumorigenesis and is amplified in various human cancers and tumor cell lines. Thus, STK15 represents an important therapeutic target for small molecule inhibitors that would disrupt its activity and block cell proliferation. The availability of a robust and selective small molecule inhibitor would also provide a useful tool for identification of the potential role of STK15 in cell cycle regulation and tumor development. The authors report the development of a novel, fast, simple microplate assay for STK15 activity suitable for high-throughput screening. In the assay, γ-33 P-ATP and STK15 were incubated in a myelin basic protein (MBP)-coated FlashPlate® to generate a scintillation signal. The assay was reproducible, the signal-to-noise ratio was high (11) and the Z′ factor was 0.69. The assay was easily adapted to a robotic system for drug discovery programs targeting STK15. The authors also demonstrate that STK15 is regulated by phosphorylation and the N-amino terminal domain of the protein. Treatment with phosphatase inhibitors (okadaic acid) or deletion of the Namino terminal domain results in a significant increase in the enzymatic activity. (Journal of Biomolecular Screening 2004:391-397) 
INTRODUCTION
S TK15 (also known as Aurora2, BTAK, AuroraA) is the human homolog of the Aurora protein kinase from Drosophila, Ipl1 kinase from S. cerevisiae, and pEg2 from Xenopus, and is a member of a family of Aurora kinases including Aurora 1 and STK13. [1] [2] [3] [4] The STK15 gene encodes a 403 aa protein and is located on human chromosome 20q13-a region that has been found to be amplified in a variety of human tumors. [5] [6] [7] The STK15 gene itself has been shown to be amplified in more than 50% of primary colorectal cancers and 12% of primary breast tumors, as well as in breast, ovarian, colon, prostate, neuroblastoma, and cervical cell lines. 5, 6 The protein was found to be overexpressed and showed elevated kinase activity in several tumor types. 5, 6 Ectopic expression of STK15 in mouse NIH3T3 and Rat1 fibroblasts led to abnormal centrosome number (amplification) and transformation in vitro. Introduction of these cells into SCID mice gave rise to tumors. 5, 6 In STK15 regulation, 2 residues, K162 and T288, seem to be important in kinase activity. 5, 8 K162 lies in the activation loop of the kinase domain, and a mutant derivative K162R results in a kinase-inactive protein. Threonine 288 lies in a PKA phosphorylation motif, which was first suggested 5 and later proven 8, 9 to be a PKA target resulting in more active STK15, although it is more likely that phosphorylation of T288 is a degradation signal. 9 The evidence to date suggests that inhibition of Aurora family members could result in antitumor effects. [10] [11] [12] Further support for this hypothesis comes from the use of STK15 antisense oligonucleotides 13 and RNAi experiments (SL unpublished data), both of which result in cell arrest at the G2/M phase of the cell cycle.
The availability of sufficiently potent and selective small molecule inhibitors of STK15 activity would provide the opportunity to investigate the effects of inhibition on cellular function, and in animal models, and could form the basis of new anticancer drugs. We describe here a FlashPlate® high-throughput screen that has proved useful for the identification of leads for the development of STK15 inhibitors.
MATERIALS AND METHODS

Materials
FlashPlates ® (SMP400) and γ-33 p-ATP (Adenosine 5′triphosphate) (NEG602H) were obtained from NEN (NEN™ Perkin Elmer Life Sciences, Inc., Boston, MA). A broad spectrum inhibitor of protein kinase, staurosporine, was purchased from CalBiochem®. Adenosine 5′-triphosphate (ATP) disodium salt (A-7699), Myelin Basic Protein (MBP) (M-1891), and all other chemical reagents were purchased from Sigma and were of analytcal grade. The recombinant protein of GST-fusion Aurora2 was produced and purified using a baculovirus expression system and GST-affinity chromatography. The antibody against STK15 was a mouse monoclonal IAK1 from Transduction Laboratories (Oxford, UK).
Production, purification, and kinase activity of STK15
The sequence coding for truncated GST-STK15 protein (aa118-403) was cloned into pFASTBac donor plasmid (Gibco BRL, Life Technologies, Paisley, UK) using standard molecular biology techniques. The rest of the procedures were carried out according to the protocol in the manufacturer's instructions (Bac-To-Bac® Baculovirus Expression Systems, Gibco BRL, Life Technologies). STK15 recombinant baculovirus was harvested 72 h posttransfection incubation, tested for viral titer by plaque assay, and amplified by infecting a small volume (100-200 ml) of suspended Sf9 cell culture with multiplicity of infection (MOI) of 0.01 to 0.1. The amplified virus was harvested with 100-fold higher viral titer 48-72 h postinfection incubation and was used for protein production by infecting a large quantity of suspended Sf9 cell culture (1-5 liters) with MOI of 5-10 followed by 72-96 h postinfection incubation in presence of okadaic acid (50 nM). Sf9 cells were then collected by centrifugation, and the recombinant GST-STK15 protein was purified from the cells by GST-affinity chromatography using Glutathione Sepharose beads as described elsewhere. 9 For western blotting and kinase assays, cells were lysed in lysis buffer (50 mM Hepes pH 7.5, 250 mM NaCl, 0.5% NP40 with protease inhibitors), incubated on ice for 30 min, and centrifuged at 13,000 g for 15 min. The supernatant was collected, and protein concentration was estimated with the Pierce BCA assay reagent. For western blotting, samples were separated on Novex Nupage Tris-Glycine gels (Invitrogen, Paisley, UK) followed by electrophoretic transfer on PVDF membrane (Millipore, Watford, UK) and blocking in 5% nonfat milk. Immunodetection was carried out using chemiluminescence detection (Amersham, Little Chalfont, UK). The in vitro kinase assays were performed in kinase buffer (50 mM Tris pH 7.5, 10 mM NaCl, 2.5 mM MgCl 2 , 1 mM DTT) containing γ-32 P-ATP and the appropriate substrate. The reactions were incubated for 30 min at 30°C and stopped by adding sample buffer. The reactions were separated on Novex Tris-Glycine gels and dried on a vacuum gel drier for 1 h at 80°C before exposure to Kodak-Biomax XR film.
Determination of K m for ATP and coating of the 384-well Basic FlashPlate ® with potential kinase substrate
To measure the apparent K m for ATP for the STK15 enzyme in a scintillation proximity assay (SPA), the reaction was carried out as described above but with a fixed amount of labeled ATP and varying amounts of cold ATP. The counts measured were corrected for the changes in specific activity of the ATP resulting from the addition of different amounts of unlabeled ATP. The corrected data were fitted by nonlinear regression to the Michaelis-Menton equation.
MAP kinase substrate peptide (MAPpp: APRTPGGRR), MBP peptide (MBPpp: APRTPGGAA), Erk kinase substrate peptide (ERKpp: AAATGPLSPGPFA), histone H3 peptide with sequence of aa 5-18 (QTARKSTGGKAPRK), and histone H3 peptide with sequence of aa 1-24 (GGARTKQTARKSTGGKAPRKQLATKA) were tested for identification of the best substrate for the assay. For optimizing the efficient coating concentration for various potential substrates, the candidate substrates were diluted in a series of concentrations with PBS. For routine kinase assay and highthroughput screening (HTS), the selected substrate (i.e., MBP) was diluted in the most efficient concentration (100 µg/ml) with PBS. The solutions of diluted substrates were then dispensed in the wells of a 384-well Basic FlashPlate®. The plates were left at 37°C for 2 h and then at 4°C overnight. After incubation, the plates were decanted of the substrate solution and were then ready for use. For storage, the plates were left in air to dry for 5 h and were maintained at 4°C until use. For all graphs and calculations of standard deviation, we used Prism 6.0 (San Diego, CA).
High-throughput screening assays
384-well Basic Flashplates ® were coated overnight at 4°C with MBP at 100 µg/ml in PBS buffer. The plate was washed twice with PBS, and 5 µl of compound in 2% DMSO was added to each well (40 µM) followed by a 15 µl master mix of buffer (50 mM Tris pH 7.5, 10 mM NaCl, 2.5 mM MgCl 2 , 1 mM DTT), 20 µM ATP, and 0.125 µCi/well 33 P-ATP. Finally, 5 µl of the enzyme also diluted in the above buffer (500 ng/well), was added to the well to give a total reaction volume of 25 µl. At this point, the plate was shaken for approximately 2 min on a flat-bed plate shaker (Wellmix, Denley, UK) and incubated for 2 h at room temperature. To stop the reaction, the plate was washed twice on a 16-pin washer (ELX50 Bio-Tek Instruments Ltd., Northstar, Bedford, UK) with 10 mM sodium pyrophosphate wash. The plate was then read on a TopCount-NXT™ (Perkin Elmer Life Sciences UK Ltd., Hounslow, UK). For screening, this assay was readily automated using the Minitrak5™ (Perkin Elmer Life Sciences UK Ltd., Hounslow, UK) for compound addition and also for addition of all other reagents except the MBP coating, which was added via a Multidrop 384 (Thermo Life Sciences, Hampshire, UK). The plates were formatted to contain controls (n = 28), positive controls (staurosporin at 200 nM, n = 4), and blanks (n = 32) on the outside columns of the 384-well plate. For assessing the performance of the HTS assay, signal-to-noise ratio (S/N) and signal-to-background ratio (S/B) were calculated using the equations S/N = meanS -meanB / √ (sd S) 2 + (sd B) 2 and S/B = meanS / meanB, respectively. The suitability of the assay for screening was assessed using the Z′ factor, 14 Z′ = 1 -(3δ s + 3δ c ) / | µ s -µ s |. The results were analyzed in OMMM and Rs3 (Accelrys, Cambridge, UK). Hits were identified as compounds that inhibited the enzyme by > 70% and were confirmed in duplicate. Potency (IC 50 ) was also determined using the same conditions.
RESULTS AND DISCUSSION
Production of highly active STK15
The aim of this work was to design a microplate format that was suitable for screening compound libraries for the identification of inhibitors of the STK15 kinase. We first produced various constructs of STK15 to test their activity. The GST-STK15 fusion fulllength protein did not provide sufficient activity for a robust assay. Previously it has been shown that Eg2-the Xenopus homologue of STK15 as well as the human STK15 is activated by okadaic acid treatment. 9, 15 Okadaic acid is a potent inhibitor of serine/threonine phosphatases. Therefore, we treated sf9 cells expressing STK15 with various concentrations of okadaic acid and performed in vitro kinase assays. We observed that the enzymatic activity of the protein increased at least 5-fold, whereas the expression levels of STK15 remained unaltered (Fig. 1B) . The signal was reduced after the treatment with λ-phosphatase as shown in Figure 1C . Having established that the human STK15 kinase activity is affected by phosphorylation, we next investigated if different truncated forms of STK15 would be more active in the in vitro assay. The results showed that we could produce approximately 10 times higher activity of the truncated protein by using only the catalytic domain (aa118-403) compared with the full-length protein (Fig. 1D) . Figure 1A shows the purity of the GST-STK15 (aa118-403), which we used in the assay. Lanes 1 and 2 represent an immunoblot using a-STK15 antibody (see Material and Methods), lane 3 is a Coomassie blue staining of the STK15 protein, and lane 4 depicts Coomassie staining of mocklysates from sf9 cells. These results showed for the first time that the protein is potentially negatively regulated by the N-terminal region, either directly or indirectly, through a binding of another protein.
Assay optimization
We initially determined the K m for the ATP to be 34 µM using the GST-catalytic domain of the STK15 protein ( Fig. 2A) . In general, kinase screening assays are run at ATP concentrations below the K m to provide bias toward ATP-competitive compounds. Based on these studies, we decided to use a concentration of 20 µM of cold ATP in the reaction. Next, using a scintillating microplate assay we tested the substrate specificity of the recombinant GST-STK15 (aa118-403). A good signal was obtained by coating the plate directly with a panel of substrates for identification of the most suitable substate for this assay. Figure 2B shows that the best result was obtained using the full-length MBP protein as a substrate. A signal of more than 20,000 cpm was obtained for the phosphorylation activity of STK15 on full-length MBP, whereas much lower signals were obtained for the rest of the panel of substrates including the MPB peptide. Unexpectedly, the 2 histone H3 substrates that include the serine 10 also gave low signals. In several studies, serine 10 of the histone H3 has been characterized as the phosphorylation site for the STK15 kinase. 16 In an attempt to develop a nonradioactive homogeneous method, we performed a LANCE assay. 17 In this we used biotinylated histone H3 peptide as substrate and GST-STK15 (aa118-403) enzyme. After the addition into the reaction of streptavidin-XL-allophycocyanin (APC) and Europium-labeled anti-GST antibody, we measured streptavidin-APC and Europium at 665 nm and 615 nm, respectively. The results showed a poor S/N ratio (2.5) in comparison with the FlashPlate® assay (8) . Therefore, we chose to use the FlashPlate® assay in a 384-well format because of its simplicity and good S/N ratio. In addition, this method has been used successfully for identification of small molecule inhibitors of histone acetyltransferases in our institute. 18 The actual concentrations used in the reaction of both the enzyme and substrate were measured (Fig. 3A, B) . We titrated the concentration of the MBP substrate solution to coat the plate, and an increase in the resulting enzyme activity was seen up to 100 µg/ ml of substrate coating solution. It is not known what proportion of the substrate actually binds to the plate. Our main purpose, in this particular kinase assay, was to identify the most effective substrate showing a wide window of signal to noise reflecting the activity levels of STK15 enzyme. In this regard, MBP full length showed the best results. In this assay, the maximal binding of the fulllength MBP occurs from solutions of~100 µg/ml. With regard to the relationship between activity and enzyme concentration, the activity was linear up to~100 µg/ml STK15 and plateaued at higher enzyme concentrations. This was probably due to depletion of one or other substrate. Thus, the concentration of 50-100 µg/ml of the STK15 showed an excellent S/B ratio (65) and S/N ratio (11) . The IC 50 for staurosporin, a general kinase inhibitor, was determined in the same format using 100 µg/ml enzyme and 100 µg/ ml MPB substrate and was found to be 150 ± 8.4 nM, calculated in 3 separate experiments in triplicate. The literature has described various IC 50 values for staurosporine inhibition with a range from low nanomolar to micromolar for a panel of Ser/Thr or Tyr protein kinases. 19 The inhibition curve is presented in Figure 4A . The DMSO tolerance of the assay is shown in Figure 4B . Even 10% DMSO had only a minor effect on the S/N ratio. The STK15 activity was not significantly different at room temperature and 37°C, and the signal was shown to be linear over a long period of incubation (0-16 h, data not shown). The condition chosen for subsequent work were 100 µg/ml GST-STK15-catalytic domain (aa118-403), 100 µg/ml full-length MBP, 20 µM ATP, and 0.125 µCi/well 33 P-γATP. This final protocol resulted in a simple assay suitable for automated screening that gives acceptable performance characteristics. 
Screening results
Reagent concentrations and assay incubation conditions were optimized for this assay format using a fixed amount of coated MBP substrate (100 µg/ml) and 100 µg/ml enzyme. The MBPcoated assay has been used to screen the center's collection of approximately 70,000 compounds, including a library of 1700 compounds enriched for kinase inhibitor-like properties. Compounds were screened in 4 batches at a concentration of 40 µM in 0.4% DMSO. This concentration was chosen to maximize the possibility of finding hits. The reproducibility of a representative batch of plates (n = 66) run in the screen is shown in Figure 5 . In this batch of plates, mean total activity was 5323 ± 350 cpm, mean blank value was 56.6 ± 86, giving a mean S/B of 94, S/N of 15, and Z′ of 0.8. Inhibition with the positive control, staurosporin, at a concentration of 200 nM was 94.3 ± 3.2%. The overall Z factor calculated using the compound-containing wells was 0.6 ± 0.1. The screening results for the other 3 batches of plates were similar, although some plates (Z′ < 0.5) needed to be repeated. Overall performance characteristics of the screen are shown in Table 1 . Compounds were identified as hits if the enzyme activity was reduced by more than 70% in the primary screening and more than 50% in the secondary screening compared to the enzyme controls, with the purpose of eliminating false negatives. The results of these experiments are summarized in Table 1 . Using the hit criteria, 410 (0.6%) active wells were identified and only 77 of these were active in confirmation assay (overall hit rate 0.11%). The confirmation rate was approximately 20%. This is similar to confirmation rates reported elsewhere for different screens. 20 The compounds that showed confirmed activity were tested for concentration dependence, and the IC 50 values were calculated. Five compounds showed an IC 50 less than 1 µM ( Table 2 ). The dose-response curves of 3 representative hit compounds randomly selected are depicted in Figure 6 .
CONCLUSIONS
Small molecule inhibitors of STK15 with sufficient potency and selectivity would provide hypothesis testing tools to investigate the cellular effects of STK15 in metaphase/anaphase transition and oncogenesis and may also lead to the development of anticancer drugs.
We have developed a new enzymatic assay for identification of STK15 small-molecule inhibitors based on the use of a scintillating microplate assay. Experiments in vitro suggest that phosphorylation of STK15 and truncation of the N-terminus of the protein yields a significantly more active enzyme. The assay has proved to be extremely sensitive, fast, and simple. A S/N ratio over 11 was obtained, which was more than 3 times better than values obtained for the LANCE assay evaluated with the same reagents. S/B ratio was 65 and the Z′ factor 0.69. Although the different sub- strates are tested at only 1 concentration and they had a different number of phosphorylation sites, MBP full-length protein was markedly superior. The full-length MBP substrate gave approximately 10 times higher signal in comparison with an MBP peptide or with other potential substrate peptides, including histone H3 (serine10), which represents the natural substrate of STK15 in Xenopus oocyte extracts. The scintillating microplate assay was successfully used in HTS format for screening approximately 70,000 compounds for STK15 inhibition. The assay format is generally applicable to other members of the Aurora family, and a similar FlashPlate® assay for STK13 has been successfully used for counterscreening (data not shown). The final assay is extremely easy to automate and is cost-effective with automated high-throughput capabilities. Although 410 hits were identified in the screen, of these, 77 were confirmed as active in a secondary screen giving a hit rate of 0.11%. The reasons for this large false positive rate are unknown, although this could be due to systematic errors in dispensing or due to nonspecific effects at the relatively high compound concentration used in the screen. However, several series of compounds have been identified with a range of potency (0.3-40 µM) against STK15 and are currently undergoing exploratory chemistry to improve their inhibitory properties. 
